Lupin receives US FDA's nod for antifungal drug voriconazole

Gavis Pharmaceuticals Llc, the US-based subsidiary of Lupin Ltd, has received final approvals from the US Food and Drug Administration (FDA) to market its voriconazole tablet (50 mg & 200 mg) and voriconazole oral suspension (40 mg/mL) - a generic equivalent of PF Prism CV’s Vfend tablet and oral suspension. Lupin has said that it will commence promoting the products in the US shortly.
 
Voriconazole tablet and oral suspension are indicated for use in patients 12 years of age and older in the treatment of select fungal infections.
 
According to IMS MAT March 2016, Vfend tablet (50 mg & 200 mg) had US sales of $ 92.8 million, while Vfend oral suspension (40 mg/mL) had US sales of $ 15.9 million.